licensed practical nurse,
licensed practical nurse, with http://www.medical-mailings.com

licensed practical nurse,

medical mailings

News for 13-Nov-21

Source: MedicineNet Asthma General
Study Sees Link Between Insomnia, Asthma

Source: MedicineNet Asthma General
Asthma Medications

Source: MedicineNet Asthma General
ephedrine (oral)

Source: MedicineNet Asthma General
Mice May Be Key to Kids' Asthma Attacks at School

Source: MedicineNet Diabetes General
FDA OKs High-Tech Diabetes Device to Help Replace Fingerstick Tests

Source: MedicineNet Asthma General
Advair Diskus, Advair HFA (fluticasone and salmeterol oral inhaler)

Source: MedicineNet Diabetes General
Chemo More Damaging to Hearts of Diabetics: Study

Source: MedicineNet Asthma General
Cured Meats Could Aggravate Asthma, Study Suggests

Source: MedicineNet Asthma General
Bronchodilators (Drug Class)

Source: MedicineNet Asthma General
Oximetry

Search the Web
licensed practical nurse,
cape outpatient surgery
medical diagnostic systems
web triage
medical doctor
gog
book doctor
Radiotherapy
ask the doctor
morbid obesity

The Best licensed practical nurse, website

All the licensed practical nurse, information you need to know about is right here. Presented and researched by http://www.medical-mailings.com. We've searched the information super highway far and wide to provide you with the best licensed practical nurse, site on the internet today. The links below will assist you in your efforts to find the information that you are looking for about
licensed practical nurse,.

licensed practical nurse,

medical mailings, email campaigns
Need information on Medical Mailings? Our links will provide you with information on all type of type of Medical Mailings for Physicians over the internet including email and snail mail. For conferencing services to go with your email campagin go to Meetings on the Net - http://www.meetingsonthenet.com
medical mailings, email campaigns

If you're still reading and haven't visited the licensed practical nurse, links yet, let me reveal how this web site happened. I was finding it extremely difficult getting the exact info I was looking for, I know some sites do have it, like the licensed practical nurse, sites I listed above, but mostly web sites don't offer to the exact thing.

Instead of searching the web and going from one licensed practical nurse, website to the next I thought I'd create my own licensed practical nurse, site, and it's obvious I've only just made a start on it. Right now I haven't really got the content I want compiled, which is why I've listed these other, more established licensed practical nurse, sites. One day soon this will be the best place to visit to find information or buy. Until then you'll have to be satisfied with the licensed practical nurse, listings.

licensed practical nurse,

medical mailings, email campaigns
Need information on Medical Mailings? Our links will provide you with information on all type of type of Medical Mailings for Physicians over the internet including email and snail mail. For conferencing services to go with your email campagin go to Meetings on the Net - http://www.meetingsonthenet.com
medical mailings, email campaigns

As the Internet grows and expands licensed practical nurse, traders gain more experience in offering products for sale. One of the big advantages that online licensed practical nurse, traders have over shop front licensed practical nurse, stores is that the capital costs are significantly less.

A traditional licensed practical nurse, outlet would need to employ staff, runs lots of licensed practical nurse, related advertising and pay rents or taxes. When a licensed practical nurse, business is placed online these overheads are significantly reduced.

Drug Offers Hope to Cancer Patients

 by: ARA Content

(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community.

Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer.

In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow.

In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs.

Ęterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer.

Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy.

Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce.

Ęterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005.

Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.

About The Author

Courtesy of ARA Content, www.ARAcontent.com; e-mail: info@ARAcontent.com

EDITOR'S NOTE: For more information about current trials call (888) 349-3232. For additional information, contact Paul Burroughs, director of communications, (418) 652-8525, Ext. 406. Neovastat is being developed by Ęterna Laboratories of Quebec, Canada.

To learn more about anti-angiogenesis and Ęterna Laboratories, visit the Ęterna Web site at www.aeterna.com. For more information about the NCI's clinical trials, visit http://cancertrials.nci.nih.gov.

Google

http://www.gomailings.com/
Go Antiques | Medical Newscast | Talk On The Net | Medical Newscast | RX Right!

Fantasy Baseball Online   fantasy-sports-directory   Listen On The Net